Strategic Partnerships Potential sales opportunities exist with major ultrasound equipment manufacturers and distributors, leveraging SonoCiné’s adjunct AWBUS to expand their system capabilities, as evidenced by past collaborations with Philips and existing integration with clinicians using shared ultrasound platforms.

Regulatory Advantage Target markets include regions where AWBUS has regulatory clearance or expansion potential (FDA adjunct to mammography in the US, Health Canada approved since 2011, EU approvals since 2012), enabling faster commercial reach where clinical guidelines support adjunct screening for dense breast tissue.

Clinical Validation Emphasize the peer‑reviewed multicenter trial and real‑world performance to drive clinician adoption, framing AWBUS as a validated, non‑disruptive add‑on that optimizes existing ultrasound workflows without requiring dedicated rooms.

Growth Levers Recent software innovations such as 3D whole-breast multiplanar reconstruction and ongoing IP protection present upsell and cross-sell opportunities to imaging centers seeking advanced visualization and competitive differentiation.

SMB Market Fit With a lean company size and mid‑single‑digit millions in revenue, the solution is well positioned for mid‑market hospitals and multi‑site imaging groups that leverage existing ultrasound assets, opening opportunities for multi‑unit contracts and turnkey deployment.